GlassScriptPhysician profile
Edward Lebovics
NPI 1619089513
$19,286.96
in general payments reported to CMS, 2019-2025
14 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,110 · 2021: $4,582 · 2022: $212 · 2023: $141 · 2024: $149 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $14,550.66 | 2019-2021 | |
| Abbvie INC. | $3,756.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.43 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $222.43 | 2019-2025 | Stelara, Simponi, Tremfya |
| Boston Scientific Corporation | $174.33 | 2019-2025 | Overstitch Endoscopic Suturing System |
| Celgene Corporation | $105.71 | 2022-2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $56.28 | 2021-2025 | Givlaari |
| Novo Nordisk INC | $45.12 | 2025 | Wegovy |
| Ardelyx, INC. | $41.29 | 2025 | Ibsrela |
| Pfizer INC. | $30.84 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $16.59 | 2025 | |
| Madrigal Pharmaceuticals | $15.97 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.80 | 2024 | Xifaxan, Plenvu |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lebovics listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.